Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

Table 1

Patient characteristics according to the treatment group.

	TIL + IL-2 (𝑛=44)	IL-2 (𝑛=44)
Primary tumor site*
Head	7	0
Trunk	20	22
Limbs	16	20
Extremities	1	1
Breslow**
<1.5	9 (0.8±0.1)	9 (1.2±0.1)
>1.5	31 (4.3±0.5)	33 (3.6±0.3)
Invaded nodes
=1	15	19
>1	29	25
Capsular breaking***
Yes	23	22
No	20	21

∗Primary tumor site unknown for one IL-2 patient, **data not available for 4 TIL patients and 2 IL-2 patients, and ***data not available for 1 TIL patient and 1 IL-2 patient.